The $800M offering at a 6.2% discount to the prior close ($133.26) creates immediate selling pressure and dilutes existing holders by ~8%. Monitor the stock for continued weakness as the 60-day lock-up on ~1.18M shares from insiders expires. The NDA submission timeline (Q4 2026) is the next major catalyst, but the large cash raise signals management expects significant commercialization costs ahead.
Price Chart
Executive Summary
Abivax is raising approximately $759.8 million in net proceeds through a public offering of 6,400,000 ADSs at $125.00 per ADS, with an underwriter option for an additional 960,000 ADSs. The offering follows positive Phase 3 ABTECT Part 2 data for obefazimod in ulcerative colitis announced on June 29, 2026, and the company plans to submit an NDA in Q4 2026. The substantial dilution (~$110.78 per ADS) and the pre-revenue clinical-stage status make this a bearish event for existing shareholders despite the positive clinical data.
Key Facts
- Offering of 6,400,000 ADSs at $125.00 per ADS for total gross proceeds of $800,000,000.
- Net proceeds to Abivax are approximately $759.8 million ($666.8 million), or $874.1 million if underwriters exercise option for 960,000 additional ADSs.
- New investors will experience immediate dilution of $110.78 per ADS in as adjusted net tangible book value.
- Pro forma cash position increases to approximately $1.1 billion (€1,105 million) from €438 million as adjusted.
- Company plans to submit NDA for obefazimod in UC to FDA in Q4 2026 following positive Phase 3 Part 2 data announced June 29, 2026.
- Net proceeds intended for US commercialization of obefazimod, clinical R&D in UC and Crohn's disease, and general corporate purposes.
- Underwriters have a 30-day option to purchase up to an additional 960,000 ADSs.
- Directors and executive officers subject to 60-day lock-up from date of prospectus supplement.
Financial Impact
Gross proceeds of $800 million from 6,400,000 ADSs at $125.00 per ADS; net proceeds ~$759.8 million. Immediate dilution of $110.78 per ADS for new investors.
Risk Factors
- Substantial immediate dilution of $110.78 per ADS for new investors.
- Potential for further dilution from outstanding warrants and free shares (8.6M+ shares).
- Clinical-stage biotech with no product revenue; NDA submission and FDA approval are binary events.
- 60-day lock-up expiration on ~1.18M insider shares could add selling pressure.
- French foreign investment control regulations may limit non-EU investor participation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-294491 |
| Document: d111359dexfilingfees.htm | 0001193125-26-294491 |
| Document: 0001193125-26-294491-index-headers.html | 0001193125-26-294491 |
| Document: 0001193125-26-294491-index.html | 0001193125-26-294491 |
| Document: 0001193125-26-294491.txt | 0001193125-26-294491 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 6, 2026 8w ago | Institutional Cluster | $130.00 $114.04 | ▼ −12.28% | ▼ −12.88% | $94.17 (−27.56%) |
Jul 2, 2026 13w ago | 6-K | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 2, 2026 13w ago | 424B5 | $144.65 $124.33 | ▲ +14.05% | ▲ +13.63% | $94.17 (+34.90%) |
Jul 1, 2026 13w ago | Press Release | $132.56 $118.84 | ▲ +10.35% | ▲ +8.16% | $94.17 (+28.96%) |
Jun 29, 2026 13w ago | 6-K | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
Jun 29, 2026 13w ago | Press Release | $133.26 $128.00 | ▼ −3.95% | ▼ −2.92% | $94.17 (−29.33%) |
May 22, 2026 18w ago | Press Release | $126.41 $94.01 | ▼ −25.63% | ▼ −23.68% | $94.17 (−25.50%) |
Mar 23, 2026 27w ago | Press Release | $110.17 $115.99 | ▲ +5.28% | ▼ −3.62% | $94.17 (−14.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access